Kaley Wilson

Dr. Kaley Wilson is currently the Director of Business Development at Quark Venture, a Vancouver based venture capital group that invests globally in health science.  Investing out of the $500M USD Global Health Sciences Fund, Dr. Wilson works closely with Quark’s Investment Committee to identify and diligence potential investment opportunities.

Dr. Wilson is also currently the interim CEO of Sitka, a biotherapeutics company with a breakthrough nanoparticle platform technology to deliver compounds to difficult to penetrate tissues.  Sitka’s lead asset, STK-01, is Phase 1 ready and is being developed for the treatment of non-muscle invasive bladder cancer.  Dr. Wilson joined Sitka in March 2020 to raise a Series A financing to take Sitka’s lead asset into the clinic.

From January 2018 until September 2019, Dr. Wilson was also the interim CEO of ARTMS Products Inc. a global leader in the development of disruptive medical isotope production technologies. Prior to joining Quark Venture, Dr. Wilson was the Associate Director, Partnerships, at the Centre for Drug Research and Development.

Dr. Wilson is also an Advisor and Mentor for Ontario Bioscience’s Capital Access Advisory Program (CAPP), a member of GlycoNet’s Commercialization Committee, Nanomedicines Innovation Network’s (NMIN) Research Management Committee, a Director on the Board of Sitka, Canary Medical and Microbion and an Observer on the Boards PHEMI and ARTMS.

Dr. Wilson obtained her PhD from the University of British Columbia (UBC), Canada, in 2007.